Comparative metabolic changes of tissues and plasma in breast cancer patients / Erda Syerena Rosli by Rosli, Erda Syerena
UNIVERSITI TEKNOLOGI MARA
COMPARATIVE METABOLIC 
CHANGES OF TISSUES AND 
PLASMA IN BREAST CANCER
PATIENTS
ERDA SYERENA BINTI ROSLI
Thesis submitted in fulfillment 
of the requirements for the degree of 
Master of Science
Faculty of Pharmacy
September 2015
AUTHOR’S DECLARATION
I declare that the work in this thesis/dissertation was carried out in accordance with the 
regulations of Universiti Teknologi MARA. It is original and is the results of my own 
work, unless otherwise indicated or acknowledged as referenced work. This thesis has not 
been submitted to any other academic institution or non-academic institution for any 
degree or qualification.
I, hereby acknowledge that I have been supplied with the Academic Rules and 
Regulations for Postgraduate, Universiti Teknologi MARA, regulating the conduct of my 
study and research.
Name of Student 
Student I.D. No. 
Programme 
Faculty 
Title
Signature of Student 
Date
Erda Syerena Binti Rosli 
2010708411 
Master of Science 
Faculty of Pharmacy
Comparative Metabolic Changes of Tissues and 
Plasma in Breast Cancer Patients.
September 2015
ABSTRACT
Breast cancer is a common disease and one of the leading causes of cancer death among 
women in Malaysia. Indeed, in spite of the continual research for the development of this 
fatal disease, the effort is hampered due to lack of understanding on the 
pathophysiological of the heterogenous nature of breast cancer. Therefore, metabolomics 
platform has been used to study the alterations of metabolic pathways which are involved 
in the disease state. This study aimed to discover the metabolic profiles as well as some 
potential biomarkers of breast cancer patients in different stages of the disease. Hence, 
global metabolite profiling was used. Plasma samples of 22 breast cancer patients and 
healthy volunteers were compared. In addition, tumour tissue and normal tissue of 12 
breast cancer patients were analysed. Samples were subjected to Liquid Chromatography 
Mass Spectrometry Time of Flight (LCMS/QTOF). Method optimization using different 
extraction solvents was performed. Significant analysis (corrected p-value, p<0.05) and 
fold change analysis (FC^2.0) were done. All detected metabolites that have passed 
through applicable statistical methods were treated as potential biomarkers and were used 
for differential analysis. In the comparison between breast cancer patients and healthy 
volunteers, maltose and hypoxanthine which are involved in energy production and 
deoxyribonucleic acid (DNA) synthesis pathway were reported with the highest AUC 
value of 0.941 and 0.898, respectively. On the other hand, most fatty acids and lipid 
metabolites were significantly perturbated in tumour samples when compared to normal 
tissue samples. This relates to their importance in proliferation of cancer cells. 
Meanwhile, based on the patient’s estrogen receptor (ER) status, xanthine and 
hypoxanthine were observed to be down-regulated in ER negative tumour tissues 
compared to ER positive. On the other hand, spermine was up-regulated in ER negative 
tumour tissues. In tumour tissue grading status results, eicosanoid metabolites and 
spermine were found to be significantly different. From the finding, disruption of 
spermine in ER status and grading status of tumour tissues can be subjected to the degree 
of aggressiveness in tumour progression. Based on the results, we believed that these 
“potential biomarkers” can possibly be used as biomarkers for further study to improve 
the diagnosis and therapeutic strategy for breast cancer.
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CHAPTER ONE 
INTRODUCTION
1.1 RESEARCH BACKGROUND
1.1.1 Breast Cancer
Breast cancer is the most common cancer among women worldwide. A total of 
231,840 new cases of invasive breast cancer will be diagnosed among the women; and 
40,290 will die from breast cancer in US in 2015 [American Cancer Society (ACS), 
2015]. In 2006, MAKNA Malaysia reported that breast cancer was the most common 
cancer among female. In fact, between 2003 to 2005, breast cancer is the leading 
cause of cancer death in Malaysia (NCPR-Breast Cancer, 2008). These alarming 
figures have triggered the researchers specifically to explore for new therapeutic 
strategy for the disease. Many studies have been conducted to understand the disease 
to improve the prognosis by improving efficacy of breast cancer treatment. Its 
heterogeneity nature has challenged the researchers to improvise the method and 
approaches to further investigate together to understand the pathogenesis and 
regulation of this disease.
The researches are urged to identify factors which lead to progression of breast
cancer. The risk of breast cancer can be classified into genetic and non-genetic factors.
Genetically, a woman that inherits a deleterious mutation in BRCA1 gene and the
BRCA2 gene has higher risk in getting this disease (Kong et al., 2011). BRCA1 and
BRCA2 are human genes that produce tumour suppressor proteins that play role in
DNA repair ensuring the stability of the genetic material of the cells. As these genes
are mutated, the function of proteins are altered and damaged DNA will not be
repaired. In addition, the development and proliferation of breast cancer cells are
influenced by hormonal production such as estrogen and progesterone. The non-
genetic factors are usually related to age, early menarche and late menopause, late age
at childbirth (more than 35 years old), no breastfeeding, use of oral contraceptives and
post-menopausal hormones, post-menopausal obesity, alcohol consumption and
physical inactivity (Katz-Brull et al., 2002 and Baek et al., 2008).
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